##################################################################################
# Document Properties
##################################################################################
SET DOCUMENT Name = "https://doi.org/10.1016/S0140-6736(20)30628-0"
SET DOCUMENT Authors = "Yojana Gadiya"
SET DOCUMENT ContactInfo = "yojana.gadiya@scai.fraunhofer.de"
SET DOCUMENT Description = "COVID-19: consider cytokine storm syndromes and immunosuppression"

SET DOCUMENT Licenses = "Private Ownership to Fraunhofer Institute SCAI"
SET DOCUMENT Copyright = "Copyright Â© 2020 Fraunhofer Institute SCAI, All rights reserved"
SET DOCUMENT Version = "2.0.0"

##################################################################################
# NAMESPACES Section
##################################################################################

# DEFINE NAMESPACE CONSO          AS URL "https://raw.githubusercontent.com/pharmacome/conso/3c93a65dc48e6786fe29ae55aa36cf9a902fe8c6/export/conso-names.belns"
# DEFINE NAMESPACE ECCODE         AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/ec-code.belns"
# DEFINE NAMESPACE EFO            AS URL "https://raw.githubusercontent.com/pharmacome/conso/5d2c2ea6f7112421cc8089a3f021a75ab60bb373/external/efo-names.belns"
# DEFINE NAMESPACE FB             AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/fb-names.belns"
# DEFINE NAMESPACE MIRBASE        AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/mirbase-names.belns"

# DEFINE NAMESPACE ADO AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/alzheimer-disease-ontology/alzheimer-disease-ontology-1.0.2.belns"
# DEFINE NAMESPACE BRCO AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/brain-region-ontology/brain-region-ontology-1.0.0.belns"
# DEFINE NAMESPACE NIFT AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/nift/NIFT.belns"

DEFINE NAMESPACE HGNC AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hgnc/hgnc-20190708.belns"
# DEFINE NAMESPACE MGI AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mgi-mouse-genes/mgi-mouse-genes-20190128.belns"
# DEFINE NAMESPACE RGD AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/rgd-rat-genes/rgd-rat-genes-20190128.belns"
# DEFINE NAMESPACE GFAM AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hgnc-gene-families/hgnc-genefamily-names-20181221.belns"
# DEFINE NAMESPACE SCOMP AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-named-complexes/selventa-named-complexes-20190128.belns"
# DEFINE NAMESPACE SFAM AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-protein-families/selventa-protein-families-20190128.belns"
# DEFINE NAMESPACE HP AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20190130.belns"
DEFINE NAMESPACE CHEBI AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/chebi/chebi-20190708.belns"
DEFINE NAMESPACE DRUGBANK AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/drugbank/drugbank-20180906.belns"
# DEFINE NAMESPACE INTERPRO AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/interpro/interpro-names-20181021.belns"
# DEFINE NAMESPACE PFAM AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/pfam/pfam-names-20181024.belns"
DEFINE NAMESPACE DO AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20200407.belns"
# DEFINE NAMESPACE GO AS URL 	"https://arty.scai.fraunhofer.de/artifactory/bel/namespace/go/go-20180109.belns"
DEFINE NAMESPACE GOBP AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/go-biological-process/go-biological-process-20190128.belns"
# DEFINE NAMESPACE GOCC AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/go-cellular-component/go-cellular-component-20190128.belns"

DEFINE NAMESPACE MESH AS URL 	"https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh/mesh-names-20181007.belns"

# DEFINE NAMESPACE MESHC AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh-chemicals/mesh-chemicals-20190128.belns"
# DEFINE NAMESPACE MESHD AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh-diseases/mesh-diseases-20190128.belns"
# DEFINE NAMESPACE MESHPP AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh-processes/mesh-processes-20190128.belns"
# DEFINE NAMESPACE MESHA AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh-anatomy/mesh-anatomy-20190128.belns"
# DEFINE NAMESPACE MESHCS AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh-cellular-structures/mesh-cellular-structures-20190128.belns"
# DEFINE NAMESPACE NCBITAXON AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/ncbi-taxonomy/ncbi-taxonomy-20200322.belns"
# DEFINE NAMESPACE FPLX           AS URL "https://raw.githubusercontent.com/sorgerlab/famplex/d9ec0526c20795146a9a6aef17496efe1a36cac6/export/famplex.belns"

# DEFINE NAMESPACE NCBIGENE AS PATTERN ".*"
# DEFINE NAMESPACE TAXONOMY       AS PATTERN "^\d+$"
# DEFINE NAMESPACE UNIPROT AS PATTERN "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\.\d+)?$"
# DEFINE NAMESPACE PUBCHEM AS PATTERN "^\d+$"
# DEFINE NAMESPACE dbSNP AS PATTERN "rs[0-9]+"
DEFINE NAMESPACE FIXME AS PATTERN ".*"

##################################################################################
# ANNOTATIONS Section
##################################################################################

# DEFINE ANNOTATION Anatomy AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20190128.belanno"
# DEFINE ANNOTATION CellLine AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20190128.belanno"
# DEFINE ANNOTATION Cell AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20190128.belanno"
# DEFINE ANNOTATION Disease AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20190128.belanno"
# DEFINE ANNOTATION MeSHAnatomy AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20190128.belanno"
# DEFINE ANNOTATION MeSHDisease AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20190128.belanno"
# DEFINE ANNOTATION Species AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/species-taxonomy-id/species-taxonomy-id-20170511.belanno"
# DEFINE ANNOTATION TextLocation AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"
# DEFINE ANNOTATION BioAssay AS PATTERN ".*"
# DEFINE ANNOTATION CellStructure AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno"
# DEFINE ANNOTATION Confidence    AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno"
# DEFINE ANNOTATION Gender        AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno"
DEFINE ANNOTATION Virus AS LIST {"SARS-CoV-2"}
# --------------------------------------------------------------------------------

##############
# Statements #
##############
SET Citation = {"DOI", "https://doi.org/10.1016/S0140-6736(20)30628-0"}

SET Evidence = "However, in hyperinflammation, immunosuppression is likely to be beneficial. Re-analysis of data from a phase 3 randomised controlled trial of IL-1 blockade (anakinra) in sepsis, showed significant survival benefit in patients with hyperinflammation, without increased adverse events.[8]"
#DB00026 - anakinra
path(MESH:Immunosuppression) neg bp(GOBP:"chronic inflammatory response")
a(DRUGBANK:DB00026) -| p(HGNC:IL1A)
a(DRUGBANK:DB00026) neg path(MESH:Sepsis)
a(DRUGBANK:DB00026) neg bp(GOBP:"chronic inflammatory response")

SET Evidence = "A multicentre, randomised controlled trial of tocilizumab (IL-6 receptor blockade, licensed for cytokine release syndrome), has been approved in patients with COVID-19 pneumonia and elevated IL-6 in China (ChiCTR2000029765) [9]. Janus kinase (JAK) inhibition could affect both inflammation and cellular viral entry in COVID-19 [10]."
#tocilizumab - DB06273
a(DRUGBANK:DB06273) -| p(HGNC:IL6R)
p(HGNC:IL6R) -- path(FIXME:"cytokine release syndrome")
SET Virus = "SARS-CoV-2"
p(HGNC:IL6R) neg path(DO:"viral pneumonia")
UNSET Virus
bp(GOBP:"activation of Janus kinase activity") -- bp(GOBP:"inflammatory response")
bp(GOBP:"activation of Janus kinase activity") -- bp(GOBP:"viral entry into host cell")

SET Evidence = "All patients with severe COVID-19 should be screened for hyperinflammation using laboratory trends (eg, increasing ferritin, decreasing platelet counts, or erythrocyte sedimentation rate) and the HScore [11] (table) to identify the subgroup of patients for whom immunosuppression could improve mortality."
bp(GOBP:"chronic inflammatory response") -> a(CHEBI:Ferritin)
bp(GOBP:"chronic inflammatory response") -| path(MESH:"Platelet Count")
bp(GOBP:"chronic inflammatory response") -- path(MESH:"Blood Sedimentation")

SET Evidence = "Therapeutic options include steroids, intravenous immunoglobulin, selective cytokine blockade (eg, anakinra or tocilizumab) and JAK inhibition."
#for COVID-19
#tocilizumab - DB06273, anakinra - DB00026
a(CHEBI:steroid) -| path(DO:"COVID-19")
a(MESH:Immunoglobulins) -| path(DO:"COVID-19")
a(DRUGBANK:DB00026) -| path(DO:"COVID-19")
a(DRUGBANK:DB06273) -| path(DO:"COVID-19")
p(MESH:"Janus Kinases") pos path(DO:"COVID-19")
